Found: 5
Select item for more details and to access through your institution.
Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta.
- Published in:
- Multiple Sclerosis Journal, 2018, v. 24, n. 13, p. 1725, doi. 10.1177/1352458517729464
- By:
- Publication type:
- Article
Summary of worldwide pediatric malignancies reported after exposure to etanercept.
- Published in:
- Pediatric Rheumatology, 2010, v. 8, p. 18, doi. 10.1186/1546-0096-8-18
- By:
- Publication type:
- Article
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies.
- Published in:
- Psoriasis Forum, 2010, n. 3, p. 3, doi. 10.1177/247553031016a00301
- By:
- Publication type:
- Article
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
- Published in:
- Neurology & Therapy, 2016, v. 5, n. 2, p. 169, doi. 10.1007/s40120-016-0048-2
- By:
- Publication type:
- Article